Goldman Sachs

AbbVie enjoyed the undivided attention of US bond investors on Tuesday when it hit the market with a $30bn 10 tranche deal that, remarkably for such a big deal, priced with a negative new issue concession.

A trio of triple-B rated companies brought bond sales totalling €2.75bn on Thursday, as a primary market abuzz with official stimulus roared towards the year's close.

Investors looked beyond Nanyang Commercial Bank's Hong Kong home to its Chinese parent this week, allowing the borrower to close a $700m Basel III-compliant tier two subordinated deal, despite the protests happening in the city.

Alibaba Group Holdings got the greenlight from Hong Kong's stock exchange for a listing that could be worth as much as $15bn. The deal looks set to receive strong anchor demand from Chinese investors.

New York Stock Exchange-listed gaming company Sea is bookbuilding for a convertible bond worth at least $1bn.

Oil major BP and motorbike maker Harley-Davidson both hit the euro bond market on Tuesday, in the wake of the European Central Bank’s far bigger than expected first week of corporate bond purchases.

Intesa Sanpaolo and Landesbank Hessen-Thüringen (Helaba) gave investors the chance to put money into preferred senior paper on Tuesday. Both trades attracted chunky order books and gave away a small new issue premium.

Pharmaron Beijing Co, a pharmaceutical research and development service platform, has launched its Hong Kong SAR flotation, aiming to raise up to HK$4.6bn ($587.8m), said a source familiar with the matter.

After more than two decades with Goldman Sachs, India co-chief executive officer Vijay Karnani is set to retire at the end of the year, according to a memo seen by GlobalCapital Asia.

Ball Corporation, a US metal packaging and aerospace technology company, is looking to cut its financing costs with a €900m issue of senior unsecured notes. Crown, its closest peer in metal packaging, set a new floor — just 0.75% — for high yield coupons in Europe in October.

Chinese biotechnological company Venus Medtech (Hangzhou) is set to launch its Hong Kong IPO, having lined up an international syndicate to run the deal.

Royal Dutch Shell’s choice this week of a tight syndicate, heavy with US banks, to lead $4bn and €3bn of bonds has laid bare the sense of vulnerability among banks outside the US bulge bracket, as some expressed resentment at being left out of a lucrative and prestigious mandate.